Option Care Health (OPCH)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$24.21-1.02%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Broken: Primary pillar broken — Revenue grows at least 5% in FY26: FY26 revenue guidance ~+1.6% vs 5% target.
Option Care Health offers home infusion services with steady revenue near $5.7 billion. Management targets EPS around $1.87 in 2026 and free cash flow above $320 million. The stock trades at a low PE of 13.6, below peers, suggesting value. Recent earnings beat and stable management support recovery hopes.
Revenue growth is weak at about 1.3% year-over-year. Cash flow from operations is negative, showing poor internal funding. The chief growth officer recently left, signaling possible execution issues. Guidance is soft, and the stock is down 27% from highs, reflecting market doubts.
The market prices in about 5% revenue growth and a fair value near $27, roughly 20% below current price. Our fair value is below the Street median, reflecting cautious optimism. We differ slightly by emphasizing execution risks and cash flow weakness.
Breaks if: EPS falls below $1.75 in FY26
Breaks if: Free cash flow falls below $250 million in FY26
Management aims to improve cash flow from operating activities to support capital allocation and growth investments.
Management stated this priority in 4 quarters including 2026-Q1 and 2026-Q2. Cash from operations was negative $12.1M in 2026-Q1 but improved to positive $184M in 2026-Q2. Full year 2026 guidance targets at least $320M cash flow from operations. The trajectory shows improvement quarter-over-quarter, indicating progress toward enhancing cash flow.
“Cash provided by Q2 operating activities of $184 million.”
“Cash used in operating activities of $12.1 million.”
“Cash provided by operating activities of $35.9 million.”
“Cash provided by operating activities of $139.4 million.”
Breaks if: Departure of another C-suite officer within next 4 quarters
Breaks if: YoY revenue growth falls below 3% in FY26
Management is focused on reaccelerating the revenue growth trajectory to position the company for sustainable long-term growth.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and a May 2026 investor presentation. Revenue grew modestly from $1.351B in 2026-Q1 to $1.442B in 2026-Q2 (+1.9% YoY). Full year 2026 revenue guidance was narrowed to $5.675B-$5.775B from prior $5.8B-$6.0B. Management is reiterating focus on reaccelerating growth but revenue growth remains modest, indicating limited progress so far.
“We further position the company for a sustainable long-term growth trajectory.”
“We are taking decisive actions to re-accelerate our growth trajectory and position us for greater long-term value creation.”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on improving operational metrics. The current thesis is intact, driven by recent earnings beats, but faces challenges in revenue growth and cash flow enhancement.
The market appears to have priced in a neutral valuation relative to peers, indicating a modest expectations gap. The current valuation suggests that while there is some fragility in execution quality, it is not fully reflected in the stock's pricing.
Fundamentals may show mixed progress as management works to reaccelerate revenue growth and enhance cash flow. Recent results indicate improvement in cash flow from operations, but revenue growth remains modest, suggesting limited advancement in these areas.
The thesis hinges on management's ability to meet guidance and improve revenue growth. Additionally, external factors such as sector performance and economic conditions will play a crucial role in shaping OPCH's trajectory.
Overall, OPCH's performance is strong, but it faces risks that could impact its growth. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.